MCID: PYR010
MIFTS: 54

Peyronie's Disease

Categories: Reproductive diseases, Rare diseases

Aliases & Classifications for Peyronie's Disease

MalaCards integrated aliases for Peyronie's Disease:

Name: Peyronie's Disease 38 12 14
Peyronie Disease 12 69
Balanitis Xerotica Obliterans 69
Induratio Penis Plastica 12
Peyronie's Fibromatosis 12
Peyronies Disease 38
Penile Induration 41

Classifications:



External Ids:

Disease Ontology 12 DOID:8616
ICD10 32 N48.6
ICD9CM 34 607.85
MeSH 41 D010411
NCIt 46 C3316
UMLS 69 C0030848

Summaries for Peyronie's Disease

MalaCards based summary : Peyronie's Disease, also known as peyronie disease, is related to peyronie disease and dupuytren contracture. An important gene associated with Peyronie's Disease is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Acetylcholine and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, prostate and bone, and related phenotypes are cellular and craniofacial

Wikipedia : 72 Peyronie\'s disease is a connective tissue disorder involving the growth of fibrous plaques in the soft... more...

Related Diseases for Peyronie's Disease

Diseases in the Peyronie Disease family:

Peyronie's Disease

Diseases related to Peyronie's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
# Related Disease Score Top Affiliating Genes
1 peyronie disease 33.9 IFNA2 SMAD3 TGFB1
2 dupuytren contracture 31.6 DCN TGFB1
3 ledderhose disease 10.9
4 giant hemangioma 10.3 IFNA2 TGFB1
5 loeys-dietz syndrome 4 10.2 TGFB2 TGFB3
6 stiff skin syndrome 10.2 TGFB1 TGFB2
7 multilocular clear cell renal cell carcinoma 10.2 TGFB2 TGFB3
8 adenosquamous pancreas carcinoma 10.1 IFNA2 SMAD4
9 hypertrophic scars 10.1 SMAD3 TGFB1 TGFB3
10 tuberculoid leprosy 10.1 TGFB1 TGFB2 TGFB3
11 tuberculous meningitis 10.0 CCL2 TGFB1
12 loeys-dietz syndrome 10.0 SMAD3 TGFB2 TGFB3
13 macular holes 10.0 CCL2 TGFB2
14 localized scleroderma 10.0 DCN SMAD3 TGFB1
15 urinary tract obstruction 10.0 CCL2 SMAD3 TGFB1
16 hereditary hemorrhagic telangiectasia 10.0 SMAD4 TGFB1 TGFB2
17 pulmonary fibrosis 9.9 CCL2 SMAD3 TGFB1
18 vitreoretinopathy, neovascular inflammatory 9.9 CCL2 TGFB1 TGFB2
19 pustulosis palmaris et plantaris 9.9 SMAD7 TGFB1
20 uveitis 9.9 CCL2 IFNA2 TGFB2
21 pulmonary fibrosis, idiopathic 9.9 CCL2 SMAD3 TGFB1
22 hypochondrogenesis 9.9 SMAD3 SMAD7 TGFB3
23 tendinosis 9.8 DCN TGFB2
24 penile disease 9.8 DCN IFNA2 SMAD3 TGFB1
25 nephrosclerosis 9.7 CCL2 TGFB1
26 mucositis 9.7
27 colitis 9.7 SMAD3 SMAD4 SMAD7
28 ureteral disease 9.5 CCL2 SMAD3 SMAD7 TGFB1
29 renal fibrosis 9.5 CCL2 SMAD3 SMAD7 TGFB1
30 inflammatory bowel disease 9.3 CCL2 SMAD3 SMAD7 TGFB1
31 keloids 9.3 DCN SMAD3 SMAD7 TGFB1 TGFB3
32 pancreatic cancer 9.2 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2
33 nephrogenic systemic fibrosis 9.2 DCN SMAD3 SMAD4 SMAD7 TGFB1
34 colorectal cancer 8.7 IFNA2 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2

Comorbidity relations with Peyronie's Disease via Phenotypic Disease Network (PDN):


Bladder Neck Obstruction Prostatic Hypertrophy
Urethral Stricture

Graphical network of the top 20 diseases related to Peyronie's Disease:



Diseases related to Peyronie's Disease

Symptoms & Phenotypes for Peyronie's Disease

MGI Mouse Phenotypes related to Peyronie's Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 SMAD3 SMAD4 SMAD7 DCN TGFB1 TGFB2
2 craniofacial MP:0005382 10 TGFB2 SMAD4 DCN SMAD7 TGFB1 SMAD3
3 digestive/alimentary MP:0005381 9.98 TGFB2 SMAD4 DCN SMAD7 TGFB1 SMAD3
4 embryo MP:0005380 9.88 TGFB2 SMAD4 SMAD7 TGFB1 SMAD3 TGFB3
5 hematopoietic system MP:0005397 9.87 TGFB2 SMAD4 DCN SMAD7 TGFB1 SMAD3
6 immune system MP:0005387 9.86 TGFB2 SMAD4 CCL2 DCN SMAD7 TGFB1
7 endocrine/exocrine gland MP:0005379 9.85 SMAD4 SMAD7 DCN TGFB1 SMAD3 TGFB2
8 renal/urinary system MP:0005367 9.55 TGFB2 SMAD4 DCN TGFB1 SMAD3
9 reproductive system MP:0005389 9.43 TGFB2 SMAD4 DCN SMAD7 TGFB1 SMAD3
10 skeleton MP:0005390 9.1 TGFB2 SMAD4 DCN TGFB1 SMAD3 TGFB3

Drugs & Therapeutics for Peyronie's Disease

Drugs for Peyronie's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 2 51-84-3 187
2
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
3 abobotulinumtoxinA Phase 2
4 Botulinum Toxins Phase 2
5 Botulinum Toxins, Type A Phase 2
6 Cholinergic Agents Phase 2
7 Neuromuscular Agents Phase 2
8 Neurotransmitter Agents Phase 2
9 onabotulinumtoxinA Phase 2
10 Peripheral Nervous System Agents Phase 2
11 Pharmaceutical Solutions Phase 2
12 Anesthetics Phase 2
13 Anesthetics, Local Phase 2
14 Anti-Arrhythmia Agents Phase 2
15 Central Nervous System Depressants Phase 2
16 Diuretics, Potassium Sparing Phase 2
17 Sodium Channel Blockers Phase 2
18
Methyltestosterone Approved Phase 1 58-18-4 6010
19
Testosterone Approved, Investigational Phase 1 58-22-0 6013
20
Ergocalciferol Approved, Nutraceutical Phase 1 50-14-6 5280793
21 Tocopherol Approved, Investigational, Nutraceutical Phase 1
22
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
23
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1 59-02-9 14985
24 Anabolic Agents Phase 1
25 Androgens Phase 1
26 Antineoplastic Agents, Hormonal Phase 1
27 Antioxidants Phase 1
28 Bone Density Conservation Agents Phase 1
29 Ergocalciferols Phase 1
30 Hormone Antagonists Phase 1
31 Hormones Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
33 Micronutrients Phase 1
34 Protective Agents Phase 1
35 Testosterone 17 beta-cypionate Phase 1
36
Testosterone enanthate Phase 1 315-37-7 9416
37 Testosterone undecanoate Phase 1
38 Tocopherols Phase 1
39 Tocotrienols Phase 1
40 Trace Elements Phase 1
41 Vitamins Phase 1
42 Calciferol Nutraceutical Phase 1
43 Tocotrienol Investigational, Nutraceutical Phase 1 6829-55-6
44 Vitamin D2 Nutraceutical Phase 1
45 Phosphodiesterase 5 Inhibitors

Interventional clinical trials:

(show all 20)

# Name Status NCT ID Phase Drugs
1 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease Completed NCT01685437 Phase 3
2 A Study of AA4500 in Men With Peyronie's Disease Completed NCT01243411 Phase 3
3 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221597 Phase 3
4 Study of AA4500 in the Treatment of Peyronie's Disease Completed NCT01221623 Phase 3
5 An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease Completed NCT02267460 Phase 3
6 Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Unknown status NCT01184586 Phase 2
7 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease Completed NCT00755222 Phase 2
8 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease Completed NCT01430169 Phase 2
9 H-22411: BOTOX® for Peyronie's Disease Recruiting NCT00812838 Phase 2 100 units of Botulinum Toxin Type A
10 Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction Enrolling by invitation NCT03355963 Phase 2
11 Clostridium Histolyticum Collagenase Injection for Urethral Disease Not yet recruiting NCT02948842 Phase 2 Clostridium Histolyticum Collagenase;Lidocaine
12 Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease Unknown status NCT01578473 Phase 1 Vitamin D2;Vitamin E;Testosterone Pellets
13 Peyronie's Disease Treatment Protocol Completed NCT02072018 Phase 1 H-100;Placebo
14 Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD Completed NCT02395029 Phase 1
15 Management of Peyronie's Disease With Adipose Tissue Stem Cell Unknown status NCT02414308 Adipose tissue stem cell injection
16 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
17 Change in Penile Length Following Bilateral Nerve-Sparing Radical Prostatectomy Completed NCT00800813
18 Efficacy of Penile Traction Therapy Using a Novel Device Recruiting NCT03389854
19 Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease Active, not recruiting NCT02298829 Subjects Previously Treated with AA4500
20 Outcomes of Surgical Correction of Penile Curvature in Adult Not yet recruiting NCT03313986

Search NIH Clinical Center for Peyronie's Disease

Cochrane evidence based reviews: penile induration

Genetic Tests for Peyronie's Disease

Anatomical Context for Peyronie's Disease

MalaCards organs/tissues related to Peyronie's Disease:

38
Small Intestine, Prostate, Bone, Endothelial, Monocytes, Testes, Eye

Publications for Peyronie's Disease

Articles related to Peyronie's Disease:

(show top 50) (show all 665)
# Title Authors Year
1
Surgical correction of Peyronie's disease via tunica albuginea plication: long-term follow-up. ( 29195031 )
2018
2
Peyronie's disease and Dupuytren's contracture secondary to topical timolol. ( 29423783 )
2018
3
Grafts for Peyronie's disease: a comprehensive review. ( 29266877 )
2018
4
The PICS Technique: A Novel Approach for Residual Curvature Correction During Penile Prosthesis Implantation in Patients With Severe Peyronie's Disease Using the Collagen Fleece TachoSil. ( 29325832 )
2018
5
Malleable Penile Implant Is an Effective Therapeutic Option in Men With Peyronie's Disease and Erectile Dysfunction. ( 29336942 )
2018
6
Re: Extracorporeal Shock Wave Therapy (ESWT) in Urology: A Systematic Review of Outcome in Peyronie's Disease, Erectile Dysfunction, and Chronic Pelvic Pain. ( 29449032 )
2018
7
Clinical Factors Negatively Impacting Sexual Relationships in Men With Peyronie's Disease. ( 29144850 )
2017
8
Three-Dimensional Photography for Quantitative Assessment of Penile Volume-Loss Deformities in Peyronie's Disease. ( 28460995 )
2017
9
Serious complications of collagenase clostridium histiolyticum injection for Peyronie's disease: more than meets the eye! ( 28540246 )
2017
10
Role of interleukin-6 and pentraxin 3 as an early marker in Peyronie's disease. ( 28359407 )
2017
11
Penile prosthetic surgery for the management of Peyronie's disease. ( 29238661 )
2017
12
Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application. ( 28791261 )
2017
13
Sonographic patterns of Peyronie's disease in patients with absence of palpable plaques. ( 29211402 )
2017
14
Recent Pathophysiological Aspects of Peyronie's Disease: Role of Free Radicals, Rationale, and Therapeutic Implications for Antioxidant Treatment-Literature Review. ( 28744308 )
2017
15
Moving from Consensus- to Evidence-Based Clinical Practice Guidelines for Peyronie's Disease. ( 28065352 )
2017
16
Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. ( 28554517 )
2017
17
Repeated Micro-Trauma of the Penile Tunica Albuginea: A New Animal Model of Peyronie's Disease. ( 29151107 )
2017
18
Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. ( 28718527 )
2017
19
Re: Bicentric Prospective Evaluation of Corporoplasty with Porcine Small Intestinal Submucosa (SIS) in Patients with Severe Peyronie's Disease. ( 29144916 )
2017
20
Effect of Penile Traction and Vacuum Erectile Device for Peyronie's Disease in an Animal Model. ( 28923308 )
2017
21
Safety and Efficacy of Collagenase Clostridium histolyticum in the Treatment of Acute-Phase Peyronie's Disease. ( 28874331 )
2017
22
Racial variations in response to intralesional collagenase clostridium histolyticum in men with Peyronie's disease. ( 29184788 )
2017
23
Does Transfer Capacitive Resistive Energy Has a Therapeutic Effect on Peyronie's Disease? Randomized, Single-Blind, Sham-Controlled Study on 96 Patients: Fast Pain Relief. ( 28482350 )
2017
24
Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: Review of a Minimally Invasive Treatment Option. ( 28879693 )
2017
25
The histopathological effects of intracavernosal mitomycin-C injection in a rat Peyronie's disease model. ( 29072564 )
2017
26
Peyronie's disease - Watch out for the bend. ( 28892596 )
2017
27
Response and Rebuttal to Letter to the Editor: Evidence-Based Management Guidelines on Peyronie's Disease. ( 28065353 )
2017
28
Safety and effectiveness of collagenase clostridium histolyticum in the treatment of Peyronie's disease using a new modified shortened protocol. ( 28612401 )
2017
29
Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners. ( 28395998 )
2017
30
Re: Safety and Effectiveness of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease Using a New Modified Shortened Protocol. ( 29144915 )
2017
31
Conservatively Managed Peyronie's Disease-Long-term Survey Results From Patients Undergoing Nonsurgical and Noninjection Therapies. ( 29174623 )
2017
32
The combination of penile revascularization surgery with penile corrective techniques as an alternative to prosthesis implantation in patients with peyronie's disease accompanied by erectile dysfunction: Long-term results. ( 29255189 )
2017
33
Effect of collagenase Clostridium histolyticum on penile vascular and morphological parameters in patients with Peyronie's disease. ( 29184789 )
2017
34
Sexual dysfunction: Shortened CCH treatment for Peyronie's disease. ( 28675171 )
2017
35
Extracellular matrix alterations in the Peyronie's disease. ( 28721300 )
2017
36
Treatment of Peyronie's disease via preoperative intralesional collagenase clostridium histolyticum followed by placement of an inflatable penile prosthesis: the new standard of care? ( 29239395 )
2017
37
Prevalence of Peyronie's Disease-Like Symptoms in Men Presenting With Dupuytren Contractures. ( 28676223 )
2017
38
Re: Factors Associated with Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients with Peyronie Disease. ( 29144914 )
2017
39
Collagenase clostridium hystolyticum in the management of Peyronie's disease. ( 28540240 )
2017
40
Commentary on "Nondegloving technique for Peyronie's disease with penile prosthesis implantation and double dorsal-ventral patch graft". ( 29205179 )
2017
41
Surgical outcomes from limiting the use of nonabsorbable suture in tunica albuginea plication for Peyronie's disease. ( 28835714 )
2017
42
Successful Treatment of Residual Curvature in Peyronie's Disease in Men Previously Treated with Intralesional Collagenase Clostridium Histolyticum. ( 28886994 )
2017
43
Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol. ( 28874327 )
2017
44
Intralesional Injection of Hyaluronic Acid in Patients Affected With Peyronie's Disease: Preliminary Results From a Prospective, Multicenter, Pilot Study. ( 26984291 )
2016
45
Lengthening strategies for Peyronie's disease. ( 27298782 )
2016
46
The Genetic Basis of Peyronie's Disease: A Review. ( 26955480 )
2016
47
Evidence-Based Management Guidelines on Peyronie's Disease. ( 27215686 )
2016
48
Pro: does shockwave therapy have a place in the treatment of Peyronie's disease? ( 27298784 )
2016
49
Re: A Meta-analysis of Extracorporeal Shock Wave Therapy for Peyronie's Disease. ( 27567204 )
2016
50
The Prevalence of Peyronie's Disease in the United States: A Population-Based Study. ( 26907743 )
2016

Variations for Peyronie's Disease

Expression for Peyronie's Disease

Search GEO for disease gene expression data for Peyronie's Disease.

Pathways for Peyronie's Disease

Pathways related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 ACTG2 CCL2 SMAD3 SMAD4 TGFB1 TGFB2
2
Show member pathways
13.58 CCL2 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2
3
Show member pathways
13.47 CCL2 IFNA2 SMAD3 SMAD4 SMAD7 TGFB1
4
Show member pathways
13.27 ACTG2 CCL2 SMAD3 SMAD4 TGFB1 TGFB2
5
Show member pathways
12.99 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
6
Show member pathways
12.83 ACTG2 TGFB1 TGFB2 TGFB3
7 12.82 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
8
Show member pathways
12.75 SMAD3 SMAD4 SMAD7 TGFB1
9
Show member pathways
12.75 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
10
Show member pathways
12.68 DCN TGFB1 TGFB2 TGFB3
11
Show member pathways
12.6 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
12
Show member pathways
12.51 IFNA2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
13
Show member pathways
12.49 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
14
Show member pathways
12.46 CCL2 IFNA2 SMAD3 TGFB1 TGFB2 TGFB3
15 12.43 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
16 12.37 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
17
Show member pathways
12.29 SMAD3 SMAD4 SMAD7 TGFB1
18
Show member pathways
12.27 TGFB1 TGFB2 TGFB3
19
Show member pathways
12.27 SMAD3 SMAD4 SMAD7
20 12.23 IFNA2 TGFB1 TGFB2 TGFB3
21 12.23 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
22 12.22 DCN TGFB1 TGFB2
23
Show member pathways
12.22 SMAD3 SMAD4 TGFB1 TGFB2
24
Show member pathways
12.19 TGFB1 TGFB2 TGFB3
25 12.18 SMAD3 TGFB1 TGFB2 TGFB3
26 12.17 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
27
Show member pathways
12.14 TGFB1 TGFB2 TGFB3
28
Show member pathways
12.12 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
29 12.09 SMAD3 SMAD4 SMAD7 TGFB1
30
Show member pathways
12.06 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
31 12.03 SMAD3 SMAD4 SMAD7 TGFB1 TGFB2 TGFB3
32 11.96 SMAD3 SMAD4 TGFB1
33 11.96 ACTG2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
34 11.94 DCN TGFB1 TGFB2 TGFB3
35 11.92 SMAD3 SMAD4 TGFB1
36 11.89 CCL2 TGFB1 TGFB2 TGFB3
37 11.87 TGFB1 TGFB2 TGFB3
38 11.87 CCL2 TGFB1 TGFB2 TGFB3
39
Show member pathways
11.86 SMAD3 SMAD4 TGFB1
40
Show member pathways
11.79 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
41
Show member pathways
11.77 SMAD3 SMAD4 TGFB1
42 11.77 SMAD3 SMAD4 SMAD7
43 11.76 SMAD3 SMAD4 SMAD7 TGFB1
44
Show member pathways
11.74 TGFB1 TGFB2 TGFB3
45
Show member pathways
11.74 SMAD3 SMAD4 SMAD7 TGFB1
46 11.73 CCL2 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
47 11.69 TGFB1 TGFB2 TGFB3
48 11.67 CCL2 SMAD7 TGFB1
49 11.66 TGFB1 TGFB2 TGFB3
50 11.65 SMAD3 SMAD4 SMAD7 TGFB1

GO Terms for Peyronie's Disease

Cellular components related to Peyronie's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.56 DCN TGFB1 TGFB2 TGFB3
2 transcription factor complex GO:0005667 9.5 SMAD3 SMAD4 SMAD7
3 extracellular space GO:0005615 9.17 ACTG2 CCL2 DCN IFNA2 TGFB1 TGFB2
4 SMAD protein complex GO:0071141 9.16 SMAD3 SMAD4
5 platelet alpha granule lumen GO:0031093 9.13 TGFB1 TGFB2 TGFB3

Biological processes related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.95 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
2 negative regulation of gene expression GO:0010629 9.91 IFNA2 TGFB1 TGFB2
3 in utero embryonic development GO:0001701 9.9 SMAD3 SMAD4 TGFB3
4 aging GO:0007568 9.89 DCN TGFB1 TGFB3
5 cytokine-mediated signaling pathway GO:0019221 9.89 CCL2 DCN IFNA2
6 cell cycle arrest GO:0007050 9.89 SMAD3 TGFB1 TGFB2
7 negative regulation of cell growth GO:0030308 9.89 SMAD3 SMAD4 TGFB1 TGFB2
8 platelet degranulation GO:0002576 9.88 TGFB1 TGFB2 TGFB3
9 kidney development GO:0001822 9.88 DCN SMAD4 TGFB2
10 palate development GO:0060021 9.87 SMAD4 TGFB2 TGFB3
11 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.87 SMAD3 SMAD7 TGFB1 TGFB3
12 cellular response to transforming growth factor beta stimulus GO:0071560 9.86 SMAD3 SMAD7 TGFB1
13 inner ear development GO:0048839 9.85 TGFB1 TGFB2 TGFB3
14 cell development GO:0048468 9.84 TGFB1 TGFB2 TGFB3
15 positive regulation of cell division GO:0051781 9.84 TGFB1 TGFB2 TGFB3
16 ureteric bud development GO:0001657 9.83 SMAD3 SMAD7 TGFB1
17 extrinsic apoptotic signaling pathway GO:0097191 9.83 SMAD3 TGFB1 TGFB2
18 response to progesterone GO:0032570 9.83 TGFB1 TGFB2 TGFB3
19 wound healing GO:0042060 9.83 DCN SMAD3 TGFB1 TGFB2 TGFB3
20 positive regulation of protein secretion GO:0050714 9.82 TGFB1 TGFB2 TGFB3
21 positive regulation of bone mineralization GO:0030501 9.81 SMAD3 TGFB1 TGFB3
22 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.81 SMAD4 TGFB1 TGFB2 TGFB3
23 BMP signaling pathway GO:0030509 9.8 SMAD4 SMAD7 TGFB1 TGFB2 TGFB3
24 ventricular septum morphogenesis GO:0060412 9.79 SMAD4 SMAD7 TGFB2
25 endoderm development GO:0007492 9.78 SMAD3 SMAD4 TGFB1
26 cell growth GO:0016049 9.77 TGFB1 TGFB2 TGFB3
27 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.76 SMAD3 TGFB1 TGFB2
28 pathway-restricted SMAD protein phosphorylation GO:0060389 9.75 SMAD7 TGFB1 TGFB2
29 epithelial to mesenchymal transition GO:0001837 9.74 TGFB1 TGFB2
30 gastrulation GO:0007369 9.74 SMAD3 SMAD4
31 digestive tract development GO:0048565 9.74 TGFB1 TGFB3
32 mammary gland development GO:0030879 9.74 TGFB1 TGFB3
33 odontogenesis GO:0042476 9.74 TGFB2 TGFB3
34 negative regulation of mitotic cell cycle GO:0045930 9.73 SMAD3 TGFB1
35 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 CCL2 TGFB1
36 face morphogenesis GO:0060325 9.73 TGFB1 TGFB3
37 developmental growth GO:0048589 9.73 SMAD3 SMAD4
38 salivary gland morphogenesis GO:0007435 9.73 TGFB1 TGFB2 TGFB3
39 outflow tract septum morphogenesis GO:0003148 9.72 SMAD4 TGFB2
40 ventricular cardiac muscle tissue morphogenesis GO:0055010 9.72 SMAD7 TGFB1
41 positive regulation of collagen biosynthetic process GO:0032967 9.72 TGFB1 TGFB3
42 negative regulation of DNA replication GO:0008156 9.71 TGFB1 TGFB3
43 uterus development GO:0060065 9.71 SMAD4 TGFB2
44 negative regulation of immune response GO:0050777 9.71 TGFB1 TGFB2
45 SMAD protein complex assembly GO:0007183 9.71 SMAD3 SMAD4 TGFB1
46 lens fiber cell differentiation GO:0070306 9.7 SMAD3 TGFB1
47 SMAD protein import into nucleus GO:0007184 9.7 TGFB1 TGFB2
48 response to laminar fluid shear stress GO:0034616 9.7 SMAD7 TGFB1 TGFB3
49 heart valve morphogenesis GO:0003179 9.69 TGFB1 TGFB2
50 regulation of striated muscle tissue development GO:0016202 9.69 SMAD3 TGFB1

Molecular functions related to Peyronie's Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.8 SMAD3 SMAD4 TGFB1 TGFB2 TGFB3
2 cytokine activity GO:0005125 9.77 CCL2 IFNA2 TGFB1 TGFB2 TGFB3
3 transcription regulatory region DNA binding GO:0044212 9.7 SMAD3 SMAD4 SMAD7
4 growth factor activity GO:0008083 9.65 TGFB1 TGFB2 TGFB3
5 collagen binding GO:0005518 9.62 DCN SMAD3 SMAD4 SMAD7
6 proximal promoter sequence-specific DNA binding GO:0000987 9.51 SMAD3 SMAD4
7 R-SMAD binding GO:0070412 9.49 SMAD3 SMAD4
8 I-SMAD binding GO:0070411 9.46 SMAD4 SMAD7
9 transcription factor activity, protein binding GO:0000988 9.43 SMAD3 SMAD4
10 type I transforming growth factor beta receptor binding GO:0034713 9.43 SMAD7 TGFB1 TGFB3
11 type II transforming growth factor beta receptor binding GO:0005114 9.33 TGFB1 TGFB2 TGFB3
12 transforming growth factor beta receptor binding GO:0005160 9.26 SMAD3 TGFB1 TGFB2 TGFB3
13 type III transforming growth factor beta receptor binding GO:0034714 8.8 TGFB1 TGFB2 TGFB3

Sources for Peyronie's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....